LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 605Coma, 507
Comparative effectiveness research
(CER), 117, 120
Complementary and alternative
medicine (CAM), use of, 566,
572
Complete blood count (CBC), 234
Complete remission (CR), 451, 456
Complex decongestive therapy
(CDT), 579
Comprehensive metabolic panel
(CMP), 234
Compton scattering, 88, 93
Computed tomography (CT), 71,
75, 252
of chest, for thymoma, 520, 524
contrast perfusion, 99, 103
for lung cancer, 71, 75
of ovarian cancer, 168, 181
Confidence interval (CI), 72, 76,
242
Constipation
in cancer patients, agents for, 553,
557
chemotherapy agents and, 555,
559
herbal treatment for, 592, 596
Continuous hyperfractionated
accelerated radiation therapy
(CHART), 87, 92
Contrast-enhanced MRI, CNS
tumors and, 389
COPP/ABVD, 426, 435
Cordotomy, 570
Core needle biopsy, 80, 83
Corticosteroids, indication for use
of, 566, 571
Cowden syndrome, 154, 160, 263,
332, 341
COX-2.SeeCyclooxygenase-2
(COX-2)
CpG island, 7, 15
CR.SeeComplete remission (CR)
Craniopharyngioma, diabetes
insipidus and, 386, 392
Critical weight loss, 565, 571
Cronic lymphocytic leukemia
(CLL), 450
absolute lymphocyte count in,
451, 455
alemtuzumab in, 452, 456
complete blood count, monitoring
of, 451, 455
fludarabine in, 455–456
13q deletion, 450, 454–455
Rai stage I, 451, 455
Cryptorchidism, and prophylactic
surgery, 80, 83
CSC.SeeCancer stem cells (CSC)CSF.SeeCerebrospinal fluid (CSF)
CT.SeeComputed tomography
(CT)
CTC.SeeCirculating tumor cells
(CTC)
CTLA-4, 380
and T-cells, 107, 111
Cumulative incidence, 69, 74
Curettage and debridement, 368,
373
Cushing’s syndrome, 225, 517, 522
Cutaneous T-cell antigen (CLA),
420
CXCR4, CTC expression of, 23, 31
Cyclic adenosine monophosphate
(cAMP), 7, 16
Cyclin A, 17, 26
Cyclin B, 17, 25
Cyclin D1, 2, 18
Cyclin-dependent kinases (CDK),
17, 25
Cyclins E, 17, 25
Cyclooxygenase (COX)-2, 42, 54,
243
colon cancer and, 42, 54
Cyclophosphamide, 131
and acute cardiac toxicity, 526,
531
CYP2E1 and benzene metabolism,
58, 64
Cytarabine, 24, 95, 100
and acute cardiac toxicity, 531
Cytarabine, in AML treatment,
439, 445–446
Cytochrome P450 enzymes, 33, 43
Cytokeratin 7 (CK-7), 475
Cytostatic agents, 185, 192D 0 , 86, 90
Dacarbazine, 368, 372
Daidzein, effect of, 68
DARC and CTC, 23, 31
Daunorubicin, 440, 446
DC.SeeDendritic cells (DC)
D&C.SeeDilation and curettage
(D&C)
DCIS.SeeDuctal cancer in situ
(DCIS)
Decitabine, 439, 446
Deep-heat modalities, for pain
control, 578
Deep venous thrombosis, in cancer
patients
risk factors for, 552, 556
Delirium, in dying patients, 562,
568
Dendritic cells (DC), 42, 54–55
characteristics of, 42, 54–55
Denys-Drash syndrome, 405Deoxyribonucleic acid (DNA), 85,
90
Depression, in terminally ill
patients, 563, 568
Depsipeptide, 3, 11
DES.SeeDiethylstilbestrol (DES)
Desmoid tumors, 268, 274
Desmoplastic small round cell
tumor, 491, 495
Developing countries, lung cancer
in, 72, 76
Dexamethasone, 442, 447, 464
Dexamethasone, for nausea
prophylaxis, 526, 532
DFS.SeeDisease-free survival
(DFS)
Diabetes mellitus (DM), 247
endometrial cancer and, 320,
327
Diarrhea
celiac plexus block and, 553, 557
chemotherapy agents and, 553,
557
secretory, 356, 363
VOD and, 533
DIC.SeeDisseminated
intravascular coagulation
(DIC)
Diet
cancer and, 61, 66
food frequency questionnaire, 61,
67
Diethylstilbestrol (DES), 318, 325
Differentiation syndrome, 446
Diffuse alveolar hemorrhage, 438,
444
Diffuse fibrillary astrocytoma, p53
gene alterations in, 383, 388
Diffuse large B cell lymphoma
(DLBCL), 415, 429, 498
ABC, 417, 431
autologous stem cell
transplantation, 417, 431
CHOP chemotherapy, 417, 431
GCB, 417, 431
GEP, 417, 431
R-CHOP chemoimmunotherapy
for, 418, 431–432
rituximab in, 417, 431
subtypes of, 417, 431
and SVC syndrome, 506
Diffuse neuronal hypertrophy, 354,
361
Dihydropyrimidine dehydrogenase
(DPD), 123, 129, 275
Dilation and curettage (D&C),
320
Disease-free survival (DFS), 336,
345